Top

Published in:

01-12-2017 | Original article

The Japanese Histologic Classification and T-score in the Oxford Classification system could predict renal outcome in Japanese IgA nephropathy patients

Authors: Ahmad Baseer Kaihan, Yoshinari Yasuda, Takayuki Katsuno, Sawako Kato, Takahiro Imaizumi, Takaya Ozeki, Manabu Hishida, Takanobu Nagata, Masahiko Ando, Naotake Tsuboi, Shoichi Maruyama

Published in: Clinical and Experimental Nephrology | Issue 6/2017

Abstract

Background

The Oxford Classification is utilized globally, but has not been fully validated. In this study, we conducted a comparative analysis between the Oxford Classification and Japanese Histologic Classification (JHC) to predict renal outcome in Japanese patients with IgA nephropathy (IgAN).

Methods

A retrospective cohort study including 86 adult IgAN patients was conducted. The Oxford Classification and the JHC were evaluated by 7 independent specialists. The JHC, MEST score in the Oxford Classification, and crescents were analyzed in association with renal outcome, defined as a 50% increase in serum creatinine.

Results

In multivariate analysis without the JHC, only the T score was significantly associated with renal outcome. While, a significant association was revealed only in the JHC on multivariate analysis with JHC.

Conclusions

The JHC and T score in the Oxford Classification were associated with renal outcome among Japanese patients with IgAN. Superiority of the JHC as a predictive index should be validated with larger study population and cohort studies in different ethnicities.

Tatematsu M, Yasuda Y, Morita Y, Sakamoto I, Kurata K, Naruse T, et al. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol. [Internet]. 2012; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22618296.

Donadio J V, Grande JP. IgA nephropathy. N Engl J Med [Internet]. 2002;347:738–48. Available from: http://www.nejm.org/doi/full/10.1056/NEJMra020109.

Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, Ibels LS, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003;18:1541–8.CrossRefPubMed

Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, et al. Prognosis in IgA Nephropathy: 30-Year Analysis of 1, 012 Patients at a Single Center in Japan. 2014;9.

D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. American journal of kidney diseases: the official journal of the National Kidney Foundation [Internet]. 2000;36:227–37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10922300.

Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses [Internet]. American Journal of Kidney Diseases. 1991. p. 12–9. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0025821025&partnerID=tZOtx3y1.

Szeto CC, Lai FMM, To KF, Yuk-Hwa Wong T, Chow KM, Cheung-Lung Choi P, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.CrossRefPubMed

Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol JASN. 2011;22:752–61.CrossRefPubMed

Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrology Dialysis. Transplantation. 2009;24:3068–74.

10.

Ikee R, Kobayashi S, Saigusa T, Namikoshi T, Yamada M, Hemmi N, et al. Impact of hypertension and hypertension-related vascular lesions in IgA nephropathy. Hypertens Res Off J Jpn Soc Hypertens [Internet]. 2006;29:15–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16715649.

11.

Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis Off J Natl Kidney Found [Internet]. 2001;38:728–35. Available from: http://www.sciencedirect.com/science/article/pii/S0272638601420440.

12.

Lee SMK, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, et al. IgA nephropathy: Morphologic predictors of progressive renal disease. Hum Pathol. 1982;13:314–22.CrossRefPubMed

13.

Meadow SR, Glasgow EF, White RHR, Moncrieff MW, Cameron JS, Ogg CS. Schönlein—henoch nephritis. QJM. 1972;41:241–60.PubMed

14.

Alamartine E, Sabatier JC, Berthoux FC. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol [Internet]. 1990;34:45–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2225552.

15.

Katafuchi R, Kiyoshi Y, Oh Y, Uesugi N, Ikeda K, Yanase T, et al. Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation. 1998;49:9491278.

16.

Lee HS, Koh HI, Lee HB, Park HC. IgA nephropathy in Korea: a morphological and clinical study. Clin Nephrol. 1987;27:131–40.PubMed

17.

Manno C, Strippoli GFM, D’Altri C, Torres D, Rossini M, Schena FP. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007;49:763–75.CrossRefPubMed

18.

Radford MG, Donadio JV, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. Journal of the American Society of Nephrology: JASN. 1997;8:199–207.PubMed

19.

Shlgematsu H. Histological grading and staging of IgA nephropathy. 1997;194–202.

20.

Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H.S. Lee’s glomerular grading system. Nephrol Dial Transplant. 2005;20:342–8.CrossRefPubMed

21.

Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis Off J National Kidney Found. 1997;29:829–42.CrossRef

22.

Cattran DC, Coppo R, Cook HT, Feehally J, Roberts ISD, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.CrossRefPubMed

23.

Roberts ISD, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:546–56.CrossRefPubMed

24.

Kawamura T, Joh K, Okonogi H, Koike K, Utsunomiya Y, Miyazaki Y, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: Emphasis on end-stage renal disease. J Nephrol. 2013;26:350–7.CrossRefPubMed

25.

Sato R, Joh K, Komatsuda A, Ohtani H, Okuyama S, Togashi M, et al. Validation of the Japanese histologic classification 2013 of immunoglobulin A nephropathy for prediction of long-term prognosis in a Japanese single-center cohort. Clin Exp Nephrol [Internet]. Springer Japan; 2015;19:411–8. Available from: http://link.springer.com/10.1007/s10157-014-1004-z.

26.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed

27.

Of OJOS, Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements [Internet]. 2013;3:4–4. Available from: http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO CKD-MBD GL KI Suppl 113.pdf%5Cn. http://www.nature.com/doifinder/10.1038/kisup.2012.73%5Cn, http://www.nature.com/doifinder/10.1038/kisup.2012.76.

28.

Peters HPE, Brand JAJ Van Den, Berger SP, Wetzels JFM. Immunosuppressive therapy in patients with IgA nephropathy. 284–9.

29.

J.V. DJ, J.P. G, E.J. B, R.A. D, T.S. L, D.C. S. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol [Internet]. 1999;10:1772–7. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=1999272369.

30.

Lee H, Hwang JH, Paik JH, Ryu HJ, Kim DK, Chin HJ, et al. Long-term prognosis of clinically early IgA nephropathy is not always favorable. BMC nephrologyyr [Internet]. 2014;15:94. Available from: /pmc/articles/PMC4070337/?report = abstract.CrossRefPubMedPubMedCentral

31.

Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet [Internet]. 1999;353:883–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10093981.

32.

Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011;2806–13.

33.

Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney international [Internet]. 2014;86:828–36. Available from: http://www.nature.com.e.bibl.liu.se/ki/journal/v86/n4/full/ki201463a.html.

34.

Lee H, Yi SH, Seo MS, Hyun JN, Jeon JS, Noh H, et al. Validation of the oxford classification of IgA nephropathy: A single-center study in Korean adults. Korean J Intern Med. 2012;27:293–300.CrossRefPubMedPubMedCentral

35.

Yau T, Korbet SM, Schwartz MM, Cimbaluk DJ. The Oxford Classification of IgA Nephropathy: a Retrospective Analysis. American Journal of Nephrology. 2011;435–44.

36.

Walsh M, Sar A, Lee D, Yilmaz S, Benediktsson H, Manns B, et al. Histopathologic features aid in predicting risk for progression of IgA nephropathy. Clin J Am Soc Nephrol [Internet]. 2010;5:425–30. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20089495.

37.

Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney international [Internet]. 2010;77:921–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20200498.

38.

Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al. Validation of the Oxford classification of IgA nephropathy. Kidney International [Internet]. 2011;80:310–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0085253815550266.

39.

Shi SF, Wang SX, Jiang L, Ji-Cheng L, Liu LJ, Chen YQ, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the Oxford classification. Clin J Am Soc Nephrol. 2011;6:2175–84.CrossRefPubMedPubMedCentral

40.

Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C. The use of the oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011;6:2384–8.CrossRefPubMedPubMedCentral

41.

Nasri H, Mortazavi M, Ghorbani A, Shahbazian H, Kheiri S, Baradaran A, et al. Oxford-MEST classification in IgA nephropathy patients: a report from Iran. J Nephropathol. 2012;1:31–42.CrossRefPubMedPubMedCentral

42.

Zeng CH, Le W, Ni Z, Zhang M, Miao L, Luo P, et al. A multicenter application and evaluation of the oxford classification of iga nephropathy in adult Chinese patients. Am J Kidney Dis. 2012;60:812–20.CrossRefPubMed

43.

Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Hashimura Y, et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol. 2012;27:783–92.CrossRefPubMed

44.

Kang SH, Choi SR, Park HS, Lee JY, Sun IO, Hwang HS, et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant. 2012;27:252–8.CrossRefPubMed

45.

Le W, Zeng C-H, Liu Z, Liu D, Yang Q, Lin R-X, et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC nephrology [Internet]. 2012;13:158. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3519602&tool=pmcentrez&rendertype=abstract.

46.

Kfoury H, Alsuwaida A, Hussain S, Aloudah N, Alhejaili F, Alsaad K, et al. External validation of the Oxford classification of IgA nephropathy: a retrospective study of 70 patients from Saudi Arabia. Hong Kong J Nephrol. 2014;16:29–33.CrossRef

47.

Serriello I, Polci R, Feriozzi S, Gigante A, Giulio SDI, Rosa M, et al. Extracapillary proliferation is an independent predictive factor in Immunoglobulin A nephropathy Correspondence: Background: Oxford classification of Immunoglobulin A Nephropathy. 2015;20:654–9.

48.

Ştefan G, Ismail G, Stancu S, Zugravu A, Andronesi A, Mandache E, et al. Validation study of Oxford Classification of IgA Nephropathy: the significance of extracapillary hypercellularity and mesangial IgG immunostaining. Pathol Int. 2016;66:453–9.CrossRefPubMed

Title: The Japanese Histologic Classification and T-score in the Oxford Classification system could predict renal outcome in Japanese IgA nephropathy patients
Authors: Ahmad Baseer Kaihan
Yoshinari Yasuda
Takayuki Katsuno
Sawako Kato
Takahiro Imaizumi
Takaya Ozeki
Manabu Hishida
Takanobu Nagata
Masahiko Ando
Naotake Tsuboi
Shoichi Maruyama
Publication date: 01-12-2017
Publisher: Springer Japan
Published in: Clinical and Experimental Nephrology / Issue 6/2017
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-017-1393-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2017

CD147 expression in peritoneal injury

Serum ferritin as an indicator of the development of encephalopathy in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome

Erratum to: Impact of hemoglobin levels on renal and non-renal clinical outcomes differs by chronic kidney disease stages: the Gonryo study

Retraction Note to: Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease

Erratum to: Assessment of kidney function in children by enzymatic determination of 2-h or 24-h creatinine clearance: comparison with inulin clearance

Erratum to: C3 glomerulopathy and current dilemmas

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials